<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616367</url>
  </required_header>
  <id_info>
    <org_study_id>1503M66201</org_study_id>
    <nct_id>NCT02616367</nct_id>
  </id_info>
  <brief_title>Comparison of Comparison of Ropivacaine and Liposomal Bupivacaine for Total Knee Arthroplasty</brief_title>
  <official_title>Comparison Between Ropivacaine and Liposomal Bupivacaine Periarticular Injections for Pain Relief After Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized prospective outcomes study comparing two groups of patients. One group
      will receive liposomal bupivacaine for a periarticular injection. The other will receive
      ropivacaine for periarticular injection for pain relief after Total Knee Arthroplasty. the
      primary objective of this study is to determine if liposomal bupivacaine provides superior
      pain control (decreased maximal pain scores within the first 72 hours post surgery) when
      compared to ropivacaine when injected in a periarticular injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard of care at our institution for pain relief in Total Knee Arthroplasty is
      ropivacaine injectate into the knee for acute postoperative pain relief. This provides pain
      relief for a duration of 6-18 hours after surgery. All patients in this study will also
      receive multimodal analgesia following surgery in both arms of the study. This will be the
      first study to prospectively analyze these two regimens.

      Study group 1 (ropivacaine arm) consist of 100 mL (1 mL ketorolac, 2.5 mL morphine, 28.95 mL
      normal saline, 300 mcg of epinephrine, and 200 mg ropivacaine) Study group 2 will consist of
      100 mL (one syringe with 50 mL total: 40 mL 0.25% bupivacaine, 300 mcg epinephrine, 1 mL
      ketorolac, 2.5 mL morphine, 6.5 mL normal saline) (one syringe with 50 mL total: 20 mL
      liposomal bupivacaine 30 mL normal saline). The periarticular injection will occur at the end
      of the procedure. Adequate analgesia will be defined as &lt; 3 VAS at rest and if VAS is greater
      that 3 adjustments in oral or intravenous pain medications. Postoperatively the study team
      will evaluate for any signs of complications. Pain scores and opioid usage will be recorded
      daily while the subject is in the hospital. A quality of recovery survey will be completed at
      72 hours post injection. All subjects will be contacted by phone at day 14 to determine if
      there have been any adverse events and report their pain level.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain control measure on pain scale of 1-10</measure>
    <time_frame>72 hours</time_frame>
    <description>to determine if liposomal bupivacaine provides superior pain control (decreased maximal pain control (decreased maximal pain scores) when compared to ropivacaine when injected in a periarticular injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>decreased maximal pain on pain scale of 1-10</measure>
    <time_frame>72 hours</time_frame>
    <description>Liposomal bupivacaine via a periarticular injection will result in a decreased maximal pain and improved quality of recovery when compared to ropivacaine when injected in a periarticular injection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Arthroplasty</condition>
  <condition>Replacement</condition>
  <condition>Knee</condition>
  <arm_group>
    <arm_group_label>liposomal bupivacaine Periarticular injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will consist of 100 mL (one syringe with 50 mL total: 40 mL 0.25% bupivacaine, 300 mcg epinephrine, 1 mL ketorolac, 2.5 mL morphine, 6.5 mL normal saline) (one syringe with 50 mL total: 20 mL liposomal bupivacaine 30 mL normal saline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine Periarticular Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will consist of 100 mL (1 mL ketorolac, 2.5 mL morphine, 28.95 mL normal saline, 300 mcg of epinephrine, and 200 mg ropivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal bupivacaine Periarticular injection</intervention_name>
    <description>Liposomal bupivacaine used for a periarticular injection in the knee</description>
    <arm_group_label>liposomal bupivacaine Periarticular injection</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine Periarticular Injection</intervention_name>
    <description>Periarticular Injection for the knee with ropivacaine</description>
    <arm_group_label>Ropivacaine Periarticular Injection</arm_group_label>
    <other_name>Norapin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients undergoing primary total knee arthroplasty surgery 18-80.

        Exclusion Criteria:

          -  Patient on chronic anticoagulation

          -  Allergy to local anesthetics, nsaids, or opioids

          -  Patients who remain intubated for one week after surgery or who are unable to provide
             information as to their feelings of pain post-operatively for the first week post-
             operatively

          -  Daily use of opioid for more than three weeks

          -  Lack of patient cooperation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto D Blanco</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roberto -D Blanco, M.D.</last_name>
    <phone>6126257116</phone>
    <email>rblancod@umn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacob Hutchins, M.D.</last_name>
    <phone>612-624-3064</phone>
    <email>hutc0079@umn.edu</email>
  </overall_contact_backup>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2015</study_first_posted>
  <last_update_submitted>November 25, 2015</last_update_submitted>
  <last_update_submitted_qc>November 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

